Regeneron Pharmaceuticals, Inc. $REGN Stock Bought by Vest Financial LLC

Vest Financial LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 77,214 shares of the biopharmaceutical company’s stock after acquiring an additional 28,732 shares during the quarter. Vest Financial LLC owned approximately 0.07% of Regeneron Pharmaceuticals worth $58,549,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in REGN. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $11,358,000. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $6,327,000. Oxbow Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $3,342,000. Finally, Deutsche Bank AG purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $323,249,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares of the company’s stock, valued at $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This represents a 7.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ REGN opened at $805.67 on Thursday. The stock has a market cap of $82.95 billion, a P/E ratio of 19.91, a PEG ratio of 1.37 and a beta of 0.16. The business’s fifty day simple moving average is $791.56 and its 200-day simple moving average is $722.18. Regeneron Pharmaceuticals, Inc. has a 12-month low of $572.75 and a 12-month high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the previous year, the firm posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 48.87 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Analyst Ratings Changes

Several research firms have weighed in on REGN. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Finally, Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $846.28.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.